Latest from University of Chicago Medicine Comprehensive Cancer Center

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.
 
Jason J. Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses noncutaneous melanoma.
 
Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non
Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.
Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.
Publication Bottom Border
Border Publication
x